Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus SITAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus SITAVIG.
FYCOMPA vs SITAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Sitavig (acyclovir) is a synthetic nucleoside analogue that inhibits viral DNA replication. It is phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, leading to chain termination.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
Topical: Apply one 50 mg buccal tablet to the upper gum above the incisor region once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Terminal elimination half-life is approximately 20 hours in adults with normal renal function. In patients with renal impairment (CrCl <30 mL/min), half-life increases to up to 40 hours, necessitating dose adjustment.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Primarily renal; approximately 80% of the dose is excreted unchanged in urine within 24 hours. Minor fecal excretion (less than 10%).
Category C
Category C
Anticonvulsant
Anticonvulsant